FDA Approves Baxter International, Inc. (BAX)’s FLEXBUMIN 5%, First And Only 5% Human Albumin Solution In A Flexible Container
8/4/2014 11:02:20 AM
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International, Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved FLEXBUMIN® [Albumin (Human)], USP, 5% Solution. FLEXBUMIN 5% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns and in patients undergoing cardiopulmonary bypass surgery.
Help employers find you! Check out all the jobs and post your resume.
comments powered by